Lilly Prevails Against Teva’s Patent Case, Maintains Alimta Exclusivity Until 2022

Eli Lilly & Co. had their patent sustained by a federal appeals court, barring generics manufacturer Teva Pharmaceuticals from marketing its own version of the billion-dollar cancer drug Alimta.
Source: Generic Line